Literature DB >> 16133726

Why have neuro-protectants failed?: lessons learned from stroke trials.

K W Muir1, Ph A Teal.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16133726     DOI： 10.1007/s00415-005-0933-6

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  70 in total

Review 1.  Outcome measures in acute stroke trials: a systematic review and some recommendations to improve practice.

Authors:  P W Duncan; H S Jorgensen; D T Wade
Journal:  Stroke       Date:  2000-06       Impact factor: 7.914

2.  Progression in acute stroke: value of the initial NIH stroke scale score on patient stratification in future trials.

Authors:  T J DeGraba; J M Hallenbeck; K D Pettigrew; A J Dutka; B J Kelly
Journal:  Stroke       Date:  1999-06       Impact factor: 7.914

Review 3.  Organised inpatient (stroke unit) care for stroke.

Authors: 
Journal:  Cochrane Database Syst Rev       Date:  2002

Review 4.  Management of acute stroke.

Authors:  Kennedy R Lees
Journal:  Lancet Neurol       Date:  2002-05       Impact factor: 44.182

Review 5.  Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury?

Authors:  Chrysanthy Ikonomidou; Lechoslaw Turski
Journal:  Lancet Neurol       Date:  2002-10       Impact factor: 44.182

6.  Clomethiazole acute stroke study (CLASS): results of a randomized, controlled trial of clomethiazole versus placebo in 1360 acute stroke patients.

Authors:  N G Wahlgren; K W Ranasinha; T Rosolacci; C L Franke; P M van Erven; T Ashwood; L Claesson
Journal:  Stroke       Date:  1999-01       Impact factor: 7.914

7.  Neuroprotection by excitatory amino acid antagonist augments the benefit of thrombolysis in embolic stroke in rats.

Authors:  T Sereghy; K Overgaard; G Boysen
Journal:  Stroke       Date:  1993-11       Impact factor: 7.914

8.  Multinational randomised controlled trial of lubeluzole in acute ischaemic stroke. European and Australian Lubeluzole Ischaemic Stroke Study Group.

Authors:  H C Diener
Journal:  Cerebrovasc Dis       Date:  1998 May-Jun       Impact factor: 2.762

9.  Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials.

Authors:  Werner Hacke; Geoffrey Donnan; Cesare Fieschi; Markku Kaste; Rüdiger von Kummer; Joseph P Broderick; Thomas Brott; Michael Frankel; James C Grotta; E Clarke Haley; Thomas Kwiatkowski; Steven R Levine; Chris Lewandowski; Mei Lu; Patrick Lyden; John R Marler; Suresh Patel; Barbara C Tilley; Gregory Albers; Erich Bluhmki; Manfred Wilhelm; Scott Hamilton
Journal:  Lancet       Date:  2004-03-06       Impact factor: 79.321

Review 10.  Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions.

Authors:  David J Gladstone; Sandra E Black; Antoine M Hakim
Journal:  Stroke       Date:  2002-08       Impact factor: 7.914
View more
  6 in total

1.  Ischemic Preconditioning: The Long-Awaited Savior of Neuroprotection. Has It Arrived?

Authors:  Magdy Selim; Michael Wang
Journal:  Neurotherapeutics       Date:  2015-07       Impact factor: 7.620

2.  The 2012 Feinberg Lecture: treatment swift and treatment sure.

Authors:  Jeffrey L Saver
Journal:  Stroke       Date:  2012-12-13       Impact factor: 7.914

3.  Albumin therapy in acute stroke patients.

Authors:  Dong Hoon Shin; Gyeong Joon Moon; Oh Young Bang
Journal:  J Neurol       Date:  2007-04-13       Impact factor: 4.849

4.  Tamoxifen mediated estrogen receptor activation protects against early impairment of hippocampal neuron excitability in an oxygen/glucose deprivation brain slice ischemia model.

Authors:  Huaqiu Zhang; Minjie Xie; Gary P Schools; Paul F Feustel; Wei Wang; Ting Lei; Harold K Kimelberg; Min Zhou
Journal:  Brain Res       Date:  2008-11-01       Impact factor: 3.252

Review 5.  Cell Therapy in Stroke-Cautious Steps Towards a Clinical Treatment.

Authors:  Olivier Detante; Keith Muir; Jukka Jolkkonen
Journal:  Transl Stroke Res       Date:  2017-11-17       Impact factor: 6.829

Review 6.  Magnesium: potential roles in neurovascular disease.

Authors:  Jason J Chang; William J Mack; Jeffrey L Saver; Nerses Sanossian
Journal:  Front Neurol       Date:  2014-04-15       Impact factor: 4.003
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.